Tetanus Toxoid Vaccine Market Forecasts to 2028 – Global Analysis By Type (Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, And Pertussis (Dtap) and Diphtheria And Tetanus (Dt)), Form (Quadrivalent, Pentavalent and Hexavalent), Age Group (Neonatal and Adult), End User (Hospitals And Clinics, Government Organizations and Research) and By Geography
According to Stratistics MRC, the Global Tetanus Toxoid Vaccine Market is accounted for $2.24 billion in 2022 and is expected to reach $3.40 billion by 2028 growing at a CAGR of 7.2% during the forecast period. Tetanus is prevented by building immunity against the pathogen that causes it using the tetanus toxoid vaccine, an inactive vaccine. The usual dosage is five doses given during childhood, a sixth during adolescence, and further doses every ten years. Tetanus has decreased 95% in frequency in the US since the tetanus vaccine was first developed in 1924. It is now listed on the World Health Organization's list of essential medicines. Even for pregnant women and people who have HIV, the vaccine is regarded as being very safe.
According to the World Health Organization (WHO) Report in 2022, the total number of Diptheria cases reported in India in 2019 was 9,622, compared to 8,788 in 2018. Similarly, the total number of tetanus is 7,071 is compared to the 7,000 cases in 2018.
Market Dynamics
Driver
Licensing agreements
The company can expand the reach of the product to numerous countries with relatively little effort and risk thanks to licensing agreements in the global tetanus toxoid market. For instance, Serum Institute of India Ltd. has a license from Genticel SA, a French biotechnology company that creates therapeutic vaccines, for its Vaxiclase technology. Takeda Pharmaceutical Company and Biological E. Ltd. entered into one licensing and marketing agreement in the global tetanus toxoid vaccine market, which sped up the development and delivery of affordable combination vaccines, including DTaP vaccines. For any combination vaccine containing the pertussis virus, BE has the exclusive right to use the pertussis vaccine technology developed by Takeda. The market for tetanus toxoid vaccines will grow as a result of these licensing agreements, which also benefit market vendors.
Restraint
Side effects of the toxic vaccine
The tetanus toxoid vaccine's side effects include redness and pain at the injection site, fever, fatigue, and muscle pain. The most harmful side effects of the tetanus toxoid vaccine, which affect less than one in 100,000 people, are severe allergic reactions. People who have any of these health issues, such as disorders of the nervous system or Guillain syndrome, in which the immune system attacks nerve cells, etc., may be at risk from certain tetanus vaccines. Pain at the injection site is the most common adverse reaction. This pain is the body's mild response to the injection, and it will be reduced very soon.
Opportunity
Launches of new products
In order to combat market competition, vendors use tactics like launching new products. To increase their market share, suppliers invest in creating cutting-edge and innovative tetanus toxoid vaccines. Tetraxim (DTaP-IPV), a vaccine created for kids to prevent diseases like diphtheria, pertussis, tetanus, and polio, was launched by Sanofi Pasteur India. This vaccine was developed in partnership with European vaccine manufacturer BB-NCIPD Ltd. (Bul Bio) and Stablepharma Ltd. to create a thermally stable version of the Td vaccine using the patented StablevaX formulation. The tetanus toxoid vaccine market will expand during the forecast period as a result of these new product launches.
Threat
High price of medical care
The cost of healthcare is a barrier to market expansion. When compared to other nations, healthcare services in the US are more expensive. Patients in these nations are discouraged from receiving the tetanus toxoid vaccine due to the high cost of healthcare in those nations. Patients in developing nations face difficulties due to inadequate healthcare infrastructure and limited government support in the form of reimbursement for medical expenses. These elements will consequently have a detrimental effect on the market growth for tetanus toxoid vaccines during the anticipated period.
Covid-19 Impact
The COVID-19 pandemic had a detrimental effect on the local tetanus toxoid vaccine market in 2020. However, the number of COVID-19 cases in the area decreased in 2021 as a result of the availability of COVID-19 vaccines. Tetanus toxoid vaccine demand increased as a result of the ease of COVID-related restrictions and the restoration of access to hospitals and clinics. The regional tetanus toxoid vaccine market will thus continue to expand during the forecast period as a result of these factors.
The neonatals segment is expected to be the largest during the forecast period
During the anticipated period, the market growth can be attributed to the neonatal segment. Due to its high fatality rate of 80%–100%, neonatal tetanus is one of the major causes of neonatal mortality. Due to unhygienic conditions and a lack of adequate sterile procedures, the disease is more common in rural areas, especially in low-income countries. Neonatal tetanus can be avoided, though, through vaccination with tetanus toxoid vaccines. These elements will fuel this segment's growth over the course of the forecast.
The hospitals and clinics segment is expected to have the highest CAGR during the forecast period
Hospitals and clinics are expected to experience the highest CAGR during the forecast period due to the increase in the number of private healthcare facilities and clinics in emerging economies. Considering how many individuals use their services for vaccinations and other medical requirements, due to their superior infrastructure, tools, and resources for administering immunizations, hospitals and clinics have a higher demand for tetanus toxoid vaccine. In addition, hospitals and clinics are more likely than other healthcare facilities to stock and provide a wider range of immunizations, including tetanus toxoid vaccines.
Region with largest share
Due to rising tetanus and diphtheria cases, as well as higher costs, high coverage, and adoption in this region, North America is anticipated to hold a significant market share in the global tetanus toxoid vaccine market. In the 56 probable cases reported in 2019 that were confirmed by the laboratory, there were 6 cases and 1 death, according to a World Health Organization report from May 2019. The age group of 1 to 5 year olds has the highest incidence rate among confirmed cases in 2019, according to the same source, followed by the age group of 6 to 14 year olds. The fatal case led to the death of a 5-year-old child. The towns of Tabarre and Acul du Nord in the Ouest Department and Nord Department, respectively, reported the highest cumulative incidence rates of probable cases in 2019.
Region with highest CAGR
The Asia-Pacific region is anticipated to have the highest CAGR during the forecast period. In countries with large populations in the region, such as India, Bangladesh, and Indonesia, tetanus is relatively common. Additionally, there are significant government initiatives in place to raise immunization rates, particularly among children and expectant mothers. The Government of India's Universal Immunization Program (UIP) has made tetanus toxoid vaccination for expectant women mandatory in order to prevent maternal and neonatal tetanus. The availability of inexpensive vaccinations and the presence of reputable vaccine manufacturers in the region are additional factors influencing the growth of the Asia-Pacific vaccine market.
Key players in the market
Some of the key players in Tetanus Toxoid Vaccine market include Actiza Pharmaceutical Pvt. Ltd., AJ Vaccines AS, Amson Vaccines and Pharma Pvt Ltd., Astellas Pharma, Avalon Pharma Pvt. Ltd., Bharat Biotech Ltd., CSL Ltd., Dano Vaccines and Biologicals Pvt. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Grifols SA, Incepta Vaccine Ltd., Meiji Holdings Co. Ltd., Microgen, Panacea Biotec Ltd., Sanofi, Bharat Biotech, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Valeant Pharmaceuticals and Zoetis Inc..
Key Developments
In June 2021, Merck & Co. Inc. and Sanofi collaborated to launch VAXELIS (diphtheria and tetanus toxoids vaccine) in the United States. The Food and Drug Administration approved the vaccine in 2018.
In March 2021, Stablepharma announced a collaboration with European vaccine manufacturer BB-NCIPD (Bul Bio) to develop a thermally stable version of the tetanus diphtheria (Td) vaccine using the patented StablevaX formulation and device.
Types Covered
• Monovalent Tetanus Toxoid (TT)
• Diphtheria, Tetanus, And Pertussis (Dtap)
• Diphtheria And Tetanus (Dt)
• Tetanus, Diphtheria, And Pertussis (Tdap)
• Other Types
Forms Covered
• Quadrivalent
• Pentavalent
• Hexavalent
• Other Forms
Age Groups Covered
• Neonatal
• Adult
• Other Age Groups
End Users Covered
• Hospitals And Clinics
• Government Organizations
• Research
• Other End Users
Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities,Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Tetanus Toxoid Vaccine Market, By Type
- 5.1 Introduction
- 5.2 Monovalent Tetanus Toxoid (TT)
- 5.3 Diphtheria, Tetanus, And Pertussis (Dtap)
- 5.4 Diphtheria And Tetanus (Dt)
- 5.5 Tetanus, Diphtheria, And Pertussis (Tdap)
- 5.6 Other Types
- 6 Global Tetanus Toxoid Vaccine Market, By Form
- 6.1 Introduction
- 6.2 Quadrivalent
- 6.3 Pentavalent
- 6.4 Hexavalent
- 6.5 Other Forms
- 7 Global Tetanus Toxoid Vaccine Market, By Age Group
- 7.1 Introduction
- 7.2 Neonatal
- 7.3 Adult
- 7.4 Other Age Groups
- 8 Global Tetanus Toxoid Vaccine Market, By End User
- 8.1 Introduction
- 8.2 Hospitals And Clinics
- 8.3 Government Organizations
- 8.4 Research
- 8.5 Other End Users
- 9 Global Tetanus Toxoid Vaccine Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
- 10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
- 11 Company Profiling
- 11.1 Actiza Pharmaceutical Pvt. Ltd.
- 11.2 AJ Vaccines AS
- 11.3 Amson Vaccines and Pharma Pvt Ltd.
- 11.4 Astellas Pharma
- 11.5 Avalon Pharma Pvt. Ltd.
- 11.6 Bharat Biotech Ltd.
- 11.7 CSL Ltd.
- 11.8 Dano Vaccines and Biologicals Pvt. Ltd.
- 11.9 Emergent BioSolutions Inc.
- 11.10 GlaxoSmithKline Plc
- 11.11 Grifols SA
- 11.12 Incepta Vaccine Ltd.
- 11.13 Meiji Holdings Co. Ltd.
- 11.14 Microgen
- 11.15 Panacea Biotec Ltd.
- 11.16 Sanofi, Bharat Biotech
- 11.17 Serum Institute of India Pvt. Ltd.
- 11.18 Shenzhen Kangtai Biological Products Co. Ltd.
- 11.19 Valeant Pharmaceuticals
- 11.20 Zoetis Inc.
- List of Tables
- Table 1 Global Tetanus Toxoid Vaccine Market Outlook, By Region (2020-2028) ($MN)
- Table 2 Global Tetanus Toxoid Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 3 Global Tetanus Toxoid Vaccine Market Outlook, By Monovalent Tetanus Toxoid (TT) (2020-2028) ($MN)
- Table 4 Global Tetanus Toxoid Vaccine Market Outlook, By Diphtheria, Tetanus, And Pertussis (Dtap) (2020-2028) ($MN)
- Table 5 Global Tetanus Toxoid Vaccine Market Outlook, By Diphtheria And Tetanus (Dt) (2020-2028) ($MN)
- Table 6 Global Tetanus Toxoid Vaccine Market Outlook, By Tetanus, Diphtheria, And Pertussis (Tdap) (2020-2028) ($MN)
- Table 7 Global Tetanus Toxoid Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 8 Global Tetanus Toxoid Vaccine Market Outlook, By Forms (2020-2028) ($MN)
- Table 9 Global Tetanus Toxoid Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 10 Global Tetanus Toxoid Vaccine Market Outlook, By Pentavalent (2020-2028) ($MN)
- Table 11 Global Tetanus Toxoid Vaccine Market Outlook, By Hexavalent (2020-2028) ($MN)
- Table 12 Global Tetanus Toxoid Vaccine Market Outlook, By Other Forms (2020-2028) ($MN)
- Table 13 Global Tetanus Toxoid Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 14 Global Tetanus Toxoid Vaccine Market Outlook, By Neonatal (2020-2028) ($MN)
- Table 15 Global Tetanus Toxoid Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 16 Global Tetanus Toxoid Vaccine Market Outlook, By Other Age Groups (2020-2028) ($MN)
- Table 17 Global Tetanus Toxoid Vaccine Market Outlook, By End User (2020-2028) ($MN)
- Table 18 Global Tetanus Toxoid Vaccine Market Outlook, By Hospitals And Clinics (2020-2028) ($MN)
- Table 19 Global Tetanus Toxoid Vaccine Market Outlook, By Government Organizations (2020-2028) ($MN)
- Table 20 Global Tetanus Toxoid Vaccine Market Outlook, By Research (2020-2028) ($MN)
- Table 21 Global Tetanus Toxoid Vaccine Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 22 North America Tetanus Toxoid Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 23 North America Tetanus Toxoid Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 24 North America Tetanus Toxoid Vaccine Market Outlook, By Monovalent Tetanus Toxoid (TT) (2020-2028) ($MN)
- Table 25 North America Tetanus Toxoid Vaccine Market Outlook, By Diphtheria, Tetanus, And Pertussis (Dtap) (2020-2028) ($MN)
- Table 26 North America Tetanus Toxoid Vaccine Market Outlook, By Diphtheria And Tetanus (Dt) (2020-2028) ($MN)
- Table 27 North America Tetanus Toxoid Vaccine Market Outlook, By Tetanus, Diphtheria, And Pertussis (Tdap) (2020-2028) ($MN)
- Table 28 North America Tetanus Toxoid Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 29 North America Tetanus Toxoid Vaccine Market Outlook, By Forms (2020-2028) ($MN)
- Table 30 North America Tetanus Toxoid Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 31 North America Tetanus Toxoid Vaccine Market Outlook, By Pentavalent (2020-2028) ($MN)
- Table 32 North America Tetanus Toxoid Vaccine Market Outlook, By Hexavalent (2020-2028) ($MN)
- Table 33 North America Tetanus Toxoid Vaccine Market Outlook, By Other Forms (2020-2028) ($MN)
- Table 34 North America Tetanus Toxoid Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 35 North America Tetanus Toxoid Vaccine Market Outlook, By Neonatal (2020-2028) ($MN)
- Table 36 North America Tetanus Toxoid Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 37 North America Tetanus Toxoid Vaccine Market Outlook, By Other Age Groups (2020-2028) ($MN)
- Table 38 North America Tetanus Toxoid Vaccine Market Outlook, By End User (2020-2028) ($MN)
- Table 39 North America Tetanus Toxoid Vaccine Market Outlook, By Hospitals And Clinics (2020-2028) ($MN)
- Table 40 North America Tetanus Toxoid Vaccine Market Outlook, By Government Organizations (2020-2028) ($MN)
- Table 41 North America Tetanus Toxoid Vaccine Market Outlook, By Research (2020-2028) ($MN)
- Table 42 North America Tetanus Toxoid Vaccine Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 43 Europe Tetanus Toxoid Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 44 Europe Tetanus Toxoid Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 45 Europe Tetanus Toxoid Vaccine Market Outlook, By Monovalent Tetanus Toxoid (TT) (2020-2028) ($MN)
- Table 46 Europe Tetanus Toxoid Vaccine Market Outlook, By Diphtheria, Tetanus, And Pertussis (Dtap) (2020-2028) ($MN)
- Table 47 Europe Tetanus Toxoid Vaccine Market Outlook, By Diphtheria And Tetanus (Dt) (2020-2028) ($MN)
- Table 48 Europe Tetanus Toxoid Vaccine Market Outlook, By Tetanus, Diphtheria, And Pertussis (Tdap) (2020-2028) ($MN)
- Table 49 Europe Tetanus Toxoid Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 50 Europe Tetanus Toxoid Vaccine Market Outlook, By Forms (2020-2028) ($MN)
- Table 51 Europe Tetanus Toxoid Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 52 Europe Tetanus Toxoid Vaccine Market Outlook, By Pentavalent (2020-2028) ($MN)
- Table 53 Europe Tetanus Toxoid Vaccine Market Outlook, By Hexavalent (2020-2028) ($MN)
- Table 54 Europe Tetanus Toxoid Vaccine Market Outlook, By Other Forms (2020-2028) ($MN)
- Table 55 Europe Tetanus Toxoid Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 56 Europe Tetanus Toxoid Vaccine Market Outlook, By Neonatal (2020-2028) ($MN)
- Table 57 Europe Tetanus Toxoid Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 58 Europe Tetanus Toxoid Vaccine Market Outlook, By Other Age Groups (2020-2028) ($MN)
- Table 59 Europe Tetanus Toxoid Vaccine Market Outlook, By End User (2020-2028) ($MN)
- Table 60 Europe Tetanus Toxoid Vaccine Market Outlook, By Hospitals And Clinics (2020-2028) ($MN)
- Table 61 Europe Tetanus Toxoid Vaccine Market Outlook, By Government Organizations (2020-2028) ($MN)
- Table 62 Europe Tetanus Toxoid Vaccine Market Outlook, By Research (2020-2028) ($MN)
- Table 63 Europe Tetanus Toxoid Vaccine Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 64 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 65 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 66 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Monovalent Tetanus Toxoid (TT) (2020-2028) ($MN)
- Table 67 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Diphtheria, Tetanus, And Pertussis (Dtap) (2020-2028) ($MN)
- Table 68 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Diphtheria And Tetanus (Dt) (2020-2028) ($MN)
- Table 69 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Tetanus, Diphtheria, And Pertussis (Tdap) (2020-2028) ($MN)
- Table 70 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 71 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Forms (2020-2028) ($MN)
- Table 72 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 73 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Pentavalent (2020-2028) ($MN)
- Table 74 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Hexavalent (2020-2028) ($MN)
- Table 75 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Other Forms (2020-2028) ($MN)
- Table 76 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 77 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Neonatal (2020-2028) ($MN)
- Table 78 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 79 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Other Age Groups (2020-2028) ($MN)
- Table 80 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By End User (2020-2028) ($MN)
- Table 81 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Hospitals And Clinics (2020-2028) ($MN)
- Table 82 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Government Organizations (2020-2028) ($MN)
- Table 83 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Research (2020-2028) ($MN)
- Table 84 Asia Pacific Tetanus Toxoid Vaccine Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 85 South America Tetanus Toxoid Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 86 South America Tetanus Toxoid Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 87 South America Tetanus Toxoid Vaccine Market Outlook, By Monovalent Tetanus Toxoid (TT) (2020-2028) ($MN)
- Table 88 South America Tetanus Toxoid Vaccine Market Outlook, By Diphtheria, Tetanus, And Pertussis (Dtap) (2020-2028) ($MN)
- Table 89 South America Tetanus Toxoid Vaccine Market Outlook, By Diphtheria And Tetanus (Dt) (2020-2028) ($MN)
- Table 90 South America Tetanus Toxoid Vaccine Market Outlook, By Tetanus, Diphtheria, And Pertussis (Tdap) (2020-2028) ($MN)
- Table 91 South America Tetanus Toxoid Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 92 South America Tetanus Toxoid Vaccine Market Outlook, By Forms (2020-2028) ($MN)
- Table 93 South America Tetanus Toxoid Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 94 South America Tetanus Toxoid Vaccine Market Outlook, By Pentavalent (2020-2028) ($MN)
- Table 95 South America Tetanus Toxoid Vaccine Market Outlook, By Hexavalent (2020-2028) ($MN)
- Table 96 South America Tetanus Toxoid Vaccine Market Outlook, By Other Forms (2020-2028) ($MN)
- Table 97 South America Tetanus Toxoid Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 98 South America Tetanus Toxoid Vaccine Market Outlook, By Neonatal (2020-2028) ($MN)
- Table 99 South America Tetanus Toxoid Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 100 South America Tetanus Toxoid Vaccine Market Outlook, By Other Age Groups (2020-2028) ($MN)
- Table 101 South America Tetanus Toxoid Vaccine Market Outlook, By End User (2020-2028) ($MN)
- Table 102 South America Tetanus Toxoid Vaccine Market Outlook, By Hospitals And Clinics (2020-2028) ($MN)
- Table 103 South America Tetanus Toxoid Vaccine Market Outlook, By Government Organizations (2020-2028) ($MN)
- Table 104 South America Tetanus Toxoid Vaccine Market Outlook, By Research (2020-2028) ($MN)
- Table 105 South America Tetanus Toxoid Vaccine Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 106 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 107 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 108 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Monovalent Tetanus Toxoid (TT) (2020-2028) ($MN)
- Table 109 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Diphtheria, Tetanus, And Pertussis (Dtap) (2020-2028) ($MN)
- Table 110 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Diphtheria And Tetanus (Dt) (2020-2028) ($MN)
- Table 111 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Tetanus, Diphtheria, And Pertussis (Tdap) (2020-2028) ($MN)
- Table 112 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 113 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Forms (2020-2028) ($MN)
- Table 114 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 115 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Pentavalent (2020-2028) ($MN)
- Table 116 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Hexavalent (2020-2028) ($MN)
- Table 117 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Other Forms (2020-2028) ($MN)
- Table 118 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 119 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Neonatal (2020-2028) ($MN)
- Table 120 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 121 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Other Age Groups (2020-2028) ($MN)
- Table 122 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By End User (2020-2028) ($MN)
- Table 123 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Hospitals And Clinics (2020-2028) ($MN)
- Table 124 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Government Organizations (2020-2028) ($MN)
- Table 125 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Research (2020-2028) ($MN)
- Table 126 Middle East & Africa Tetanus Toxoid Vaccine Market Outlook, By Other End Users (2020-2028) ($MN)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook